Opus Genetics, Inc.
IRD
$4.92
-$0.27-5.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.20M | 14.63M | 15.42M | 13.65M | 10.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.20M | 14.63M | 15.42M | 13.65M | 10.99M |
| Cost of Revenue | 30.75M | 27.35M | 29.92M | 29.99M | 26.84M |
| Gross Profit | -16.55M | -12.72M | -14.50M | -16.34M | -15.85M |
| SG&A Expenses | 22.05M | 24.46M | 22.37M | 19.96M | 18.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.80M | 51.81M | 52.29M | 49.95M | 45.07M |
| Operating Income | -38.60M | -37.18M | -36.87M | -36.30M | -34.07M |
| Income Before Tax | -49.59M | -68.20M | -58.28M | -58.62M | -57.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.59 | -68.20 | -58.28 | -58.62 | -57.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.59M | -68.20M | -58.28M | -58.62M | -57.53M |
| EBIT | -38.60M | -37.18M | -36.87M | -36.30M | -34.07M |
| EBITDA | -38.55M | -37.13M | -36.84M | -36.28M | -34.07M |
| EPS Basic | -0.81 | -1.76 | -1.80 | -1.99 | -2.04 |
| Normalized Basic EPS | -0.51 | -0.53 | -0.55 | -0.67 | -0.70 |
| EPS Diluted | -0.81 | -1.76 | -1.80 | -1.99 | -2.04 |
| Normalized Diluted EPS | -0.51 | -0.53 | -0.55 | -0.67 | -0.70 |
| Average Basic Shares Outstanding | 248.48M | 198.26M | 153.77M | 116.22M | 106.85M |
| Average Diluted Shares Outstanding | 248.48M | 198.26M | 153.77M | 116.22M | 106.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |